Q4 2016 · 10-K
Revenue$396.62M$396.62M +16.4% vs Q4 2015+6.0% vs Q3 2016
Net Income$116.69M$116.69M +41.0% vs Q4 2015+29.9% vs Q3 2016
EPS Diluted$1.91$1.91 +44.7% vs Q4 2015+31.7% vs Q3 2016
Gross Profit$358,958,000+14.0%
Operating Incomederived$165,504,000+55.2%
Operating Cash Flowderived$180,695,000+50.9%
Free Cash Flowderived$179,418,000+54.2%
Margins · derived
Gross margin90.5%−1.9 pt vs Q4 2015
Operating margin41.7%+10.4 pt vs Q4 2015
Net margin29.4%+5.1 pt vs Q4 2015
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2016 | Q4 2015 | Q4 2014 | Q4 2013 |
|---|---|---|---|---|
| Revenue | $396.62M | $340.88M | $328.14M | $235.77M |
| Net Income | $116.69M | $82.76M | $81.61M | $55.29M |
| EPS Diluted | $1.91 | $1.32 | $1.30 | $0.90 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR